drugset / Trial / NCT00352287

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

NCT00352287

Phase 4 Completed 60 enrolled Stanford University
RandomizedFactorialDouble-blindTreatment

Summary

The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat. Participants received a combination of two drugs: (1) recombinant human growth hormone (or its placebo) and (2) pioglitazone (or its placebo). We measured the abdominal fat content and blood sugar levels of participants before and after 40 weeks of treatment.

Timeline

Start
2003-03
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule
Subject Somatropin Protein / enzyme biologic